干扰素-α联合达沙替尼治疗慢性粒细胞白血病取得深部分子反应1例并文献复习
Deep Molecular Response by IFN-α and Dasatinib Combination with Chronic Myeloid Leukemia: Report of One Case and Review of Literature
摘要: 酪氨酸激酶抑制剂耐药在慢性粒细胞白血病中具有挑战性。我们在此报告一例慢性粒细胞白血病患者，其在干扰素-α和达沙替尼联合治疗下成功实现了完全遗传学缓解。
Abstract: Drug resistance of tyrosine kinase inhibitors is challenging in chronic myeloid leukemia. Here we report a patient with chronic myeloid leukemia who successfully achieved complete genetic remission under the combination of interferon-α and dasatinib.
文章引用：乔晗, 冯献启. 干扰素-α联合达沙替尼治疗慢性粒细胞白血病取得深部分子反应1例并文献复习[J]. 临床医学进展, 2021, 11(5): 2199-2203. https://doi.org/10.12677/ACM.2021.115316

参考文献

[1] Jabbour, E. and Kantarjian, H. (2016) Chronic Myeloid Leukemia: 2016 Update on Diagnosis, Therapy, and Monitoring. American Journal of Hematology, 91, 252-265. [Google Scholar] [CrossRef] [PubMed]
[2] Druker, B.J., Guilhot, F., O’Brien, S.G., et al. (2006) Five-Year Follow-Up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. The New England Journal of Medicine, 355, 2408-2417. [Google Scholar] [CrossRef] 
[3] Rowley, J.D. (1973) Letter: A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining. Nature, 243, 290-293. [Google Scholar] [CrossRef] [PubMed]
[4] Shtivelman, E., Lifshitz, B., Gale, R.P., et al. (1985) Fused Transcript of abl and bcr Genes in Chronic Myelogenous Leukaemia. Nature, 315, 550-554. [Google Scholar] [CrossRef] [PubMed]
[5] Daley, G.Q., Van Etten, R.A. and Baltimore, D. (1990) Induction of Chronic Myelogenous Leukemia in Mice by the P210bcr/abl Gene of the Philadelphia Chromosome. Science, 247, 824-830. [Google Scholar] [CrossRef] [PubMed]
[6] Tura, S., Baccarani, M., Zuffa, E., et al. (1994) Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia. The New England Journal of Medicine, 330, 820-825. [Google Scholar] [CrossRef] 
[7] (1997) Interferon Alfa versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-Analysis of Seven Randomized Trials: Chronic Myeloid Leukemia Trialists’ Collaborative Group. Journal of the National Cancer Institute, 89, 1616- 1620. [Google Scholar] [CrossRef] 
[8] Kantarjian, H., Shah, N.P., Hochhaus, A., et al. (2010) Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. The New England Journal of Medicine, 362, 2260-2270. [Google Scholar] [CrossRef] 
[9] O’Brien, S., Berman, E., Borghaei, H., et al. (2009) NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network, 7, 984-1023. [Google Scholar] [CrossRef] [PubMed]
[10] Haznedaroglu, I.C. (2015) Drug Therapy in the Progressed CML Patient with Multi-TKI Failure. Mediterranean Journal of Hematology and Infectious Diseases, 7, e2015014. [Google Scholar] [CrossRef] [PubMed]
[11] Ernst, T. and Hochhaus, A. (2012) Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated with Disease Progression. Seminars in Oncology, 39, 58-66. [Google Scholar] [CrossRef] [PubMed]
[12] Kim, T.D., Türkmen, S., Schwarz, M., et al. (2010) Impact of Additional Chromosomal Aberrations and BCR-ABL Kinase Domain Mutations on the Response to Nilotinib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. Haematologica, 95, 582-588. [Google Scholar] [CrossRef] [PubMed]
[13] Baccarani, M., Cortes, J., Pane, F., et al. (2009) Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European Leukemia Net. Journal of Clinical Oncology, 27, 6041-6051. [Google Scholar] [CrossRef] 
[14] Zhou, L., Shi, H., Jiang, S., et al. (2016) Deep Molecular Response by IFN-α and Dasatinib Combination in a Patient with T315I-Mutated Chronic Myeloid Leukemia. Pharmacogenomics, 17, 1159-1163. [Google Scholar] [CrossRef] [PubMed]
[15] Hjorth-Hansen, H., Stentoft, J., Richter, J., et al. (2016) Safety and Efficacy of the Combination of Pegylated Interferon-α2b and Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients. Leukemia, 30, 1853- 1860. [Google Scholar] [CrossRef] [PubMed]
[16] Essers, M.A., Offner, S., Blanco-Bose, W.E., et al. (2009) IFNalpha Activates Dormant Haematopoietic Stem Cells in Vivo. Nature, 458, 904-908. [Google Scholar] [CrossRef] [PubMed]
[17] Cornelissen, J.J., Ploemacher, R.E., Wognum, B.W., et al. (1998) An in Vitro Model for Cytogenetic Conversion in CML. Interferon-Alpha Preferentially Inhibits the Outgrowth of Malignant Stem Cells Preserved in Long-Term Culture. Journal of Clinical Investigation, 102, 976-983. [Google Scholar] [CrossRef] 

为你推荐